Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00186121
Status:
COMPLETED
Last Update Posted:
2019-10-07
First Post:
2005-09-13
Brief Title:
Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women
Sponsor:
Stanford University
Organization:
Stanford University
Study Overview
Official Title:
A Phase II Trial of Arimidex Plus Zoladex in the Treatment of Hormone Receptor Positive Metastatic Carcinoma of the Breast in Premenopausal Women
Status:
COMPLETED
Status Verified Date:
2019-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the antitumor activity toxicity and effectiveness of the combination of goserelin Zoladex and anastrozole Arimidex in the treatment of premenopausal women with hormone receptor positive metastatic carcinoma of the breast
Detailed Description:
Pre-menopausal women with estrogen andor progesterone receptor positive metastatic or recurrent breast cancer were enrolled and treated with goserelin Zoladex monthly and began anastrozole Arimidex daily for 21 days following the first injection of goserelin Participants continued on treatment until disease progression or unacceptable toxicity
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 1033VS0012 | OTHER | alternate | None |
| 75597 | OTHER | None | None |
| BRSMTS0001 | OTHER | None | None |